CHARLES ARTHUR PELOQUIN, PHARM.D. CURRICULUM VITAE, … · Internal Medicine 1989; 149: 2269-2273. 3. ... meningitis: Clinical problems and concentrations of second-line anti-tuberculous

CHARLES ARTHUR PELOQUIN, PHARM.D.

CURRICULUM VITAE, May 2014 Personal Present Rank: Professor Citizenship: USA Educational History 12/81 Bachelor of Science, Pharmacy (Magna cum Laude) University of Connecticut 5/86 Doctor of Pharmacy Philadelphia College of Pharmacy and Science Professional History 5/80 – 9/80 Medicinal Chemist 5/81 – 9/81 University of Connecticut School of Pharmacy Storrs, CT 12/81 – 7/82 Intern in Pharmacy Saint Francis Hospital and Medical Center Hartford, CT 7/82 – 6/83 A.S.H.P. Resident in Hospital Pharmacy Duke University Medical Center Durham, NC 7/83 – 2/84 Clinical Pharmacist, General Surgery Duke University Medical Center Durham, NC 3/84 – 8/84 Clinical Pharmacist, General Medicine Duke University Medical Center Durham, NC 8/84 – 3/85 Staff Pharmacist Thomas Jefferson University Hospital Philadelphia, PA 7/86 – 8/88 A.C.C.P. Fellow, Infectious Diseases and Pharmacokinetics The Clinical Pharmacokinetics Laboratory Millard Fillmore Hospital, Buffalo, NY

Charles A. Peloquin Page 2

Professional History (continued) 7/88 – 3-09 Director, Infectious Disease Pharmacokinetics Laboratory National Jewish Medical and Research Center 1400 Jackson Street, Denver, CO 80206 7/88 Assistant Faculty Member, Department of Medicine 4/94 Associate Faculty Member, Department of Medicine 7/01 Senior Faculty Member, Department of Medicine National Jewish Medical and Research Center 9/88 – 12/94 Adjoint Assistant Professor of Pharmacy 1/95 – 11/01 Adjoint Associate Professor of Pharmacy 11/01 – 9/05 Adjoint Professor of Pharmacy 9/05 – 3/09 Clinical Professor of Pharmacy University of Colorado School of Pharmacy, Denver, CO 7/93 – 12/94 Adjoint Assistant Professor of Medicine 1/95 – 11/01 Adjoint Associate Professor of Medicine 11/01 – 9/05 Adjoint Professor of Medicine 9/05 – 3/09 Clinical Professor of Medicine, Division of Infectious Diseases University of Colorado School of Medicine, Denver, CO 3/09 – present Professor, and Director of the Infectious Disease Pharmacokinetics Laboratory,

College of Pharmacy, and Emerging Pathogens Institute, University of Florida, Gainesville, FL Professional Licenses (Registered Pharmacist) 1982 State of Connecticut (#5884) 1984 Commonwealth of Pennsylvania (inactive) 1989 State of Colorado (#12831, inactive) 2009 State of Florida Clinical Lab Technologist, LTD (#TNL 42669) Honors and Awards 1980-present Rho Chi Honor Society 1981 University of Connecticut Honor Scholar 1987-1988 ACCP Infectious Disease Research Fellow 2010 FCCP, Fellow of the American College of Clinical Pharmacy Professional Affiliations 1982-2004 American Society of Health Systems Pharmacists 1989-2003 Colorado Society of Hospital Pharmacists 1995-2005 International Union Against Tuberculosis and Lung Disease 1986-present American College of Clinical Pharmacy 1990-present American Society of Microbiology 1991-present Society of Infectious Disease Pharmacists 2004-present International Society of Antimicrobial Pharmacology 2013-present National Tuberculosis Controllers Association


Journal Referee: Regular: 1990 - present Pharmacotherapy 1997 - present International Journal of Tuberculosis and Lung Disease 1997 - present Clinical Infectious Diseases 1998 - present Antimicrobial Agents and Chemotherapy 2001 - present Journal of Antimicrobial Chemotherapy Teaching Activities 2010 - present College of Pharmacy, University of Florida Undergraduate Lectures: Pharmacotherapy III and V, Infectious Diseases 2010 – present Student laboratory rotations Clinical Pharmacy Resident Shaun Berning, Pharm.D. June 1991 – May 1992 Current: Medical Science Liaison Ortho Biotech Fellows / Research Associates

Amy Bulpitt, B.S. Pharmacy, R.Ph. June 1996 to July 1997 NIH RO1 AI37845 Research Associate Current: Pharmacist, Swedish Medical Center, Denver Rocsanna Namdar, Pharm.D. June 1997 to July 1998 NIH RO1 AI37845 Research Associate Current: Assistant Professor, University of Colorado College of Pharmacy

Rebecca Malone, Pharm.D. June 1997 to July 1999

FDA Orphan Product Division FD-R-000812-01 Research Associate Current: Clinical Pharmacist, University of Arizona, Tucson, AZ Barbara Auclair, Pharm.D. November 1998 to November 1999 NIH RO1 AI37845 Research Associate Current: Pharmacist, Greenville, SC


Fellows / Research Associates

Min Zhu, Ph.D. December 1999 to September 2000 NIH RO1 AI37845 Research Associate

Current: Associate Director, Strategic Modeling & Simulation, Clinical Discovery, Bristol Myers Squibb Company, Princeton, NJ

Bryan McGee, Pharm.D. September 2007 to present CU HIV Training Grant

Graduate Students Eric Egelund, Pharm.D. August 2010 to present Aline Barth, Pharm.D. August 2011 to present Abdullah Alsultan August 2012 to present

Annual Continuing Education All requirements met for Pharmacist’s license since 1981


Bibliography A. Original research papers published in refereed journals (126 papers: 20 first author, 34 senior author, 72 other) 1. Nix DE, Sands M, Peloquin CA, Vari AJ, Cumbo TJ, Vance JW, Fracasso JF, Schentag JJ. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. American Journal of Medicine 1987; 82(suppl 4A):352. 2. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organisms, MIC, and clinical condition on bacterial eradication. Archives if Internal Medicine 1989; 149: 2269-2273. 3. Peloquin CA, James GT, McCarthy EA. Improved high-performance liquid chromatographic assay for the determination of ethionamide in serum. Journal of Chromatography 1991, 563: 472-475. 4. Peloquin CA, Cumbo TJ, Schentag JJ. Kinetics and dynamics of tobramycin action in patients with bacteriuria given single doses. Antimicrobial Agents and Chemotherapy 1991; 35: 1191-1195. 5. Peloquin CA, James GT, McCarthy EA, Goble M. Pharmacokinetics of ethionamide suppositories. Pharmacotherapy 1991; 11: 359-363. 6. Gordon SM, Horsburgh CR, Peloquin CA, Havlik JA, Metchock B, Heifets L, McGowan JE, Thompson SE. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. Journal of Infectious Diseases 1993; 168: 1559-1562. 7. Peloquin CA, Henshaw TL, Huitt GA, Berning, SE, Nitta AT, James GT. Pharmacokinetic evaluation of p-aminosalicylic acid granules. Pharmacotherapy 1994; 14: 40-46, and correction: Pharmacotherapy 1994; 14:(4) P-2. 8. Peloquin CA, James GT, Craig LD, Kim M, McCarthy EA, Iklé DN, Iseman MD. Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid pro-drug. Pharmacotherapy 1994; 14: 415-423. 9. Fish DN, Bainbridge JL, Peloquin CA. Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration. Pharmacotherapy 1995; 15: 236-245. 10. Berning SE, Madsen L, Iseman MD, Peloquin CA. Long-term safety of ofloxacin and ciprofloxacin in the treatment of Mycobacterial infections. American Journal of Respiratory and Critical Care Medicine 1995; 151: 2006-2009.


A. Original research papers published in refereed journals 11. Elliott AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tubercle and Lung Disease 1995; 76: 463-467. 12. Stetter MD, Peloquin CA. Isoniazid and rifampin therapy failure in a Colobus monkey (Colobus guereza caudatus). Journal of Zoo and Wild Life Medicine 1995; 26: 152-154. 13. Peloquin CA, Berning SE, Madsen L, Iseman MD. Ofloxacin and Ciprofloxacin in the Treatment of Mycobacterial Infections: Development of Resistance and Drug Interactions. Journal of Infectious Disease Pharmacotherapy 1995; 1: 45-65. 14. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT. Incidence of low anti-tuberculosis drug concentrations in patients with AIDS. Annals of Pharmacotherapy 1996; 30: 919-925. 15. Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT. Pharmacokinetic evaluation of thiacetazone. Pharmacotherapy 1996; 16: 735-741. 16. Peloquin CA, Berning SE. Evaluation of the Drug Interaction between Clarithromycin and Rifampin. Journal of Infectious Disease Pharmacotherapy. 1996; 2: 19-35. 17. Hafner R, Cohn JA, Wright DJ, Dunlap NE, Egorin MJ, Enama ME, Muth K, Peloquin CA, Mor N, Heifets LB and the DATRI 008 Study Group. Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis: Optimization of Methodology. Am J Respir Crit Care Med 1997; 156: 918-923. 18. Peloquin CA, Jaresko GS, Yong CL, Keung ACF, Bulpitt AE, Jelliffe RW. Population Pharmacokinetic Modeling of Isoniazid, Rifampin, and Pyrazinamide. Antimicrobial Agents and Chemotherapy 1997; 41: 2670-2679. 19. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrobial Agents and Chemotherapy. 1998; 42: 927-929. 20. Amsden GW, Cheng KL, Peloquin CA, Nafziger AN. Oral cimetidine prolongs clarithromycin absorption. Antimicrobial Agents and Chemotherapy. 1998; 42: 1578-1580. 21. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. Pharmacokinetics of Pyrazinamide Under Fasting Conditions, with Food, and with Antacids. Pharmacotherapy 1998; 18: 1205-1211. 22. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of Rifampin Under Fasting Conditions, with Food, and with Antacids. Chest 1999; 115: 12-18.


A. Original research papers published in refereed journals 23. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of Ethambutol Under Fasting Conditions, with Food, and with Antacids. Antimicrobial Agents and Chemotherapy 1999, 43; 568-572. 24. Harbeck RJ, Worthen GS, Lebo TD, Peloquin CA. Clofazimine Crystals in the Cytoplasm of Pulmonary Macrophages. Annals of Pharmacotherapy 1999; 33: 250. 25. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. Once-Daily and Twice-Daily Dosing of p-Aminosalicylic Acid (PAS) Granules. American Journal of Respiratory and Critical Care Medicine 1999, 159: 932-934. 26. Garey KW, Peloquin CA, Godo PG, Nafziger AN, Amsden GW. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother 1999;43:1152-5. 27. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999; 159: 1580-1584. 28. Wimsatt J, Johnson J, Mangone BA, Tothill A, Peloquin CA. Clarithromycin pharmacokinetics in the desert tortoise (G. agassizii) - Single and preliminary multiple dose studies. Journal of Zoo and Wild Life Medicine 1999; 30: 36-43. 29. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of Isoniazid Under Fasting Conditions, with Food, and with Antacids. International Journal of Tuberculosis and Lung Disease. 1999; 3: 703-710. 30. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. Chest 1999; 116: 984-990. 31. DeVincenzo JP, Berning SE, Peloquin CA, Husson RN. Multidrug-resistant tuberculous meningitis: Clinical problems and concentrations of second-line anti-tuberculous medications. Annals of Pharmacotherapy 1999; 33: 1184-1188. 32. Auclair B, Berning SE, Huitt GA, Peloquin CA. Potential interaction between itraconazole and clarithromycin. Pharmacotherapy 1999; 19: 1439-1444. 33. Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999; 14: 347-351.


A. Original research papers published in refereed journals 35. Anisimova Y, Gelperina S, Peloquin C, Heifets, L. Nanoparticles as antituberculosis drug carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J Nanoparticle Res 2000; 2; 165-671. 36. Auclair B, Nix DE, Adam RD, James GT, Peloquin CA. Pharmacokinetics of Ethionamide under Fasting Conditions, with Orange Juice, Food, and Antacids. Antimicrobial Agents and Chemotherapy 2001, 45: 810-814. 37. Shaikh ZHA, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scandinavian Journal of Infectious Diseases 2001; 33: 375-379. 38. Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of Cycloserine under Fasting Conditions, with Orange Juice, Food, and Antacids. Pharmacotherapy 2001; 21: 891-897. 39. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RJ, Peloquin CA. Population Pharmacokinetics of Intravenous and Intramuscular Streptomycin in Patients with Tuberculosis. Pharmacotherapy 2001; 21: 1037-1045. 40. Peloquin CA, Zhu M, Adam RD, Godo, PG, Nix DE. Pharmacokinetics of p-Aminosalicylate under Fasting Conditions, with Orange Juice, Food, and Antacids. Annals of Pharmacotherapy 2001; 35: 1332-1338. 41. Reid J, Marciniuk D, Peloquin CA, Hoeppner V. Pharmacokinetics of Antituberculosis Medications Delivered via Percutaneous Gastrojejunostomy Tube. Chest 2002; 121: 281-284. 42. Zhu M, Stambaugh JJ, Berning SE, Bulpitt AE, Hollender ES, Narita M, Ashkin D, Peloquin CA. Ofloxacin Population Pharmacokinetics in Patients with Tuberculosis. Int J Tuber Lung Dis 2002; 6: 503-509. 43. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, Peloquin CA. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22: 686-695. 44. Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis 2002; 82: 91-96.


A. Original research papers published in refereed journals 45. Spradling P, Drociuk D, McLaughlin S, Lee LM, Peloquin CA, Gallicano K, Pozsik C, Onorato I, Ridzon R. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: An institutional tuberculosis outbreak. Clinical Infectious Diseases 2002; 35: 1106-1112. 46. Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA. Linezolid stability in peritoneal dialysis solutions. Peritoneal Dialysis International 2002; 22: 419-422. 47. Auclair B, Mikota SK, Peloquin CA, Aguilar R, Maslow JN. Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci). J Zoo Wildl Med 2002; 33: 193-203. 48. Gunderson BW, Ibrahim KH, Peloquin CA, Hovde LB, Rotschafer JC. Comparison of Linezolid Activity Under Aerobic and Anaerobic Conditions Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 2003; 47: 398-399. 49. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T and the Tuberculosis Trials Consortium. Low Isoniazid Concentration Associated with Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. Am J Respir Crit Care Med. 2003 Jan 16 [e-pub ahead of print]; print version Am J Respir Crit Care Med. 2003; 167: 1341-1347. 50. Kraft MD, Pasko D, DePestel DD, Ellis J, Peloquin CA, Mueller BA. Linezolid Clearance During Continuous Venovenous Hemodiafiltration: A Case Report. Pharmacotherapy 2003, 23: 1071-1075. 51. DePestel DD, Peloquin CA, Carver PL. Peritoneal Fluid Concentrations of Linezolid in the Treatment of Vancomycin-Resistant Enterococcus faecium Peritonitis. Pharmacotherapy 2003; 23: 1322-1326. 52. Tsapis N, Bennett D, O’Driscoll K, Shea K, Lipp MM, Fu K, Clarke RW, Deaver D, Yamins D, Wright J, Peloquin CA, Weitz DA, and Edwards DA. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis 2003; 83: 379-385. 53. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Peloquin CA, Remmel RP, Chirgwin K, Salomon N, Hafner R for the ACTG 309 Team. The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clin Infect Dis 2004; 38: 556-564. 54. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling T, Hayden K, Goldberg S and the Tuberculosis Trials Consortium. Pharmacokinetics of Rifapentine 600, 900 and 1,200 mg during Once-Weekly Tuberculosis Therapy. American Journal of Respiratory and Critical Care Medicine. published ahead of print on February 12, 2004 as doi:10.1164/rccm.200311-1612OC; print version American Journal of Respiratory and Critical Care Medicine 2004; 169: 1191-1197.


A. Original research papers published in refereed journals 55. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clinical Infectious Diseases 2004; 38: 1538-1544. 56. Nix DE, Zhu M, Adam RD, Godo PG, Peloquin CA. Pharmacokinetics of Clofazimine under Fasting Conditions, with Orange Juice, Food, and Antacids. Tuberculosis 2004; 84: 365-373. 57. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, Berning SE, Jelliffe RW, Jaresko GS, Peloquin CA. Population pharmacokinetic modeling of ethambutol in children and adults with tuberculosis. International Journal of Tuberculosis and Lung Disease 2004; 8: 1360-1367. 58. Maslow JN, Mikota SK, Zhu M, Isaza R, Peddie LR, Dunker F, Peddie J, Riddle H, Peloquin CA. Population Pharmacokinetics of Isoniazid (INH) in the treatment of Mycobacterium tuberculosis among Asian and African Elephants (Elephas maximus and Loxodonta africana). Journal of Veterinary Pharmacology and Therapeutics 2005; 28: 21-27. 59. Stein GE, Schooley S, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJC. Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis. Annals of Pharmacotherapy 2005; 39: 427-432. 60. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B S, Silva-Trigo C, Zhao Z, Hodge T and the Tuberculosis Trials Consortium. Association Between Acquired Rifamycin Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and Tuberculosis. Clinical Infectious Diseases 2005; 40: 1481-1491. 61. Maslow JN, Mikota SK, Zhu M, Riddle H, Peloquin CA. Pharmacokinetics of Ethambutol (EMB) in Elephants. Journal of Veterinary Pharmacology and Therapeutics 2005; 321-323. 62. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold A, Lockman S, Oyeri R, Talbot E, Kenyon T, Moetti T, Moffat H, Peloquin CA. Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana. Clinical Infectious Diseases 2005; 41: 461-469. 63. Ciulla TA, Comer GM, Peloquin CA, Wheeler J. Human vitreous distribution of linezolid after a single oral dose. Retina. 2005; 25: 619-624. 64. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen in Murine Tuberculosis. Am J Respir Crit Care Med 2005; 172: 1457-1462. [Epub Sept 2005] 65. Zhu M, Maslow JN, Mikota SK, Isaza R, Dunker F, Riddle H, Peloquin CA. Population Pharmacokinetics of Pyraziamide in Elephants. Journal of Veterinary Pharmacology and Therapeutics J Vet Pharmacol Ther 2005; 28: 403-409.


A. Original research papers published in refereed journals 66. Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z and the Tuberculosis Trials Consortium. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clinical Infectious Diseases 2005; 41: 1343-1349. [Epub Sept 2005] 67. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R Peloquin CA for the AIDS Clinical Trials Group 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clinical Infectious Diseases 2005; 41: 1638-1647. 68. Rosenthal IM, Williams K, Tyagi S , Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006 Mar 30; [Epub ahead of print]; Am J Respir Crit Care Med 2006; 174: 94-101. 69. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. Early and Extended Early Bactericidal Activity of Levofloxacin, Gatifloxacin and Moxifloxacin in Pulmonary Tuberculosis. Int J Tuber Lung Dis 2006; 10: 605-612. 70. Mauro LS, Peloquin CA, Schmude K, Assaly R, Malhotra D. Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis. 2006; 47: e83-86. 71. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset

JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in the murine model of tuberculosis. Antomicrobial Agents and Chemotherapy 2006; 50: 2621-2625. 72. Peloquin CA, Maslow JN, Mikota SK, Forrest A, Dunker F, Isaza R, Peddie LR, Dunker F, Peddie J, Zhu M. Dose Selection and Pharmacokinetics of Rifampin in Elephants for the Treatment of Tuberculosis. Journal of Veterinary Pharmacology and Therapeutics. 2006; 29:581-5. 74. Pinheiro VGF, Ramos LMA, Monteiro HSA, Barroso EC, Bushen OY, Façanha MC, Peloquin CA, Guerrant RL, Lima AAM. Intestinal Permeability and Malabsorption of Rifampin and Isoniazid in Active Pulmonary Tuberculosis. Braz J Infect Dis. 2006 Dec;10(6):374-9. 75. Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007 May 21; [Epub ahead of print]; Antimicrob Agents Chemother 2007; 51: 2861-2866. 76. Benator D, Weiner M, Burman W, Vernon A, Zhao Z, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, and Peloquin CA for the Tuberculosis Trials Consortium. Clinical Evaluation of the Nelfinavir – Rifabutin Interaction in Patients with HIV Infection and Tuberculosis. Pharmacotherapy 2007; 27: 793-800.


A. Original research papers published in refereed journals 77. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek D. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. Journal of Antimicrobial Chemotherapy 2007; 4: 819-823. [E-Published August 1, 2007] 78. Luber A, Browner, R, Kim D, Silverman R, Peloquin CA, Frank I. Steady state pharmacokinetics (PK) of QD fosamprenavir (FPV)/ritonavir(r) and atazanavir (ATV)/r alone and in combination with 20mg of omeprazole (OMP) in healthy volunteers. HIV Medicine 2007; 8: 457-464. 79. Peloquin CA, Hadad DJ, Molion LPD, Palaci M, Boom WH, Dietze R, Johnson JL Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy 2008; 52:852-857. Epub 2007 Dec 10. PMID: 18070980 80. Rosenthal I, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger E. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007 Dec;4(12):e344. PMID: 18092886 81. Am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, Boyne M, Xu H, Gegina Y, Knudson DL, Johnson F, Peloquin CA, Slayden RA, Tonge PJ. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008; 18: 3029-3033. Epub 2008 Apr 18. PMID: 18457948 82. Schwiesow JN Iseman MD, Peloquin CA. Concomitant use of voriconazole and rifabutin in a patient with multiple infections. Pharmacotherapy 2008; 28:1076–1080. PMID: 18657024 83. Hoff D, Caraway M, Brooks E, Driver E, Ryan G, Peloquin CA, Orme IM, Basaraba RJ, Lenaerts AJ. Metronidazole lacks antibacterial activity in Guinea Pigs infected with M. tuberculosis. Antimicrobial Agents and Chemotherapy. 2008; 52: 4137-4140. Epub 2008 Aug 11. PMID: 18694944 84. Wimsatt J, Tothill A, Offermann CF, Sheehy, JG, Peloquin CA. Long-term and per rectum disposition of clarithromycin in the desert tortoise (Gopherus agassizii). J of the American Association for Laboratory Animal Science 2008; 47: 41-45. PMID: 18702450 85. Long R, Barrie J, Stewart K, Peloquin CA. Treatment of tuberculous empyema with simultaneous oral and intra-pleural anti-tuberculosis drugs. Can Respir J. 2008; 15:241-243. PMID: 18716684 86. Dooley K, Flexner C, Hackman J, Peloquin C, Nuermberger E, Chaisson RE, Dorman SE. High-dose intermittent rifapentine induces its own metabolism and that of moxifloxacin. Antimicrobial Agents and Chemotherapy. 2008; 52: 4037-4042. Epub 2008 Sep 2. PMID: 18765687


A. Original research papers published in refereed journals 87. Dietz R, Hadad DJ, McGee B. Molino LP, Maciel ELN, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom H, Palaci M, Johnson JL. Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2008; 178: 1180-1185. Epub 2008 Sep 11. PMID: 18787216 88. Sung JC, Garcia-Contreras L, VerBerkmoes JL, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DE. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrobial Agents and Chemotherapy 2009; 53: 1338-1343. Epub 2009 Jan 12. PMID: 19139288 89. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE. Therapeutic drug monitoring in patients with tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 2009; 29: 503–510. PMID: 19397460 90. Sung JC, Garcia-Contreras L, VerBerkmoes JL, Padilla DJ, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DE. Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery. Pharmaceutical Research 2009; 26: 1847-1855. Epub 2009 Apr 30. PMID: 19407933 91. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewll PC, Wells, CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. Isoniazid, Rifampin, Ethambutol and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis – Botswana. Clin Infect Dis. 2009 Jun 15;48(12):1685-94. PMID: 19432554 92. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin CA. Population Pharmacokinetics of Linezolid in Adults with Pulmonary TuberculosisAntimicrob Agents Chemother. 2009 Sep;53(9):3981-4. Epub 2009 Jun 29. PMID: 19564361 93. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse model of tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. Epub 2009 Jul 20. PMID: 19620331 94. Barroso EC, Pinheiro VGF, Facanha MC, Carvalho MRD, Moura ME, Campelo CL, Peloquin CA, Guerrant RL, Lima AAM. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg. 2009 Aug;81(2):322-9. PMID: 19635892 95. Ahmad Z, Klinkenberg KG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL, Grosset JG, Karakousis PC. Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant, Not Drug-Resistant, Mycobacterium tuberculosis in the Guinea Pig. J Infect Dis. 2009 Oct 1;200(7):1136-43.PMID: 19686043


A. Original research papers published in refereed journals 96. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009 Nov 1;49(9):1305-11. PMID: 19807276 97. Luber A, Condoluci D, Slowinski P, Andrews M, Olson K, Peloquin C, Pappa K, Pakes G; for the COL104422 Study Team. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV Med. 2010 Mar;11(3):193-9. Epub 2009 Oct 23. PMID: 19863619 98. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother. 2010 Apr;65(4):729-34. Epub 2010 Jan 31. PMID: 20123722 99. Weinberg A, Forster-Harwood J, McFarland E, Pappas J, Davies J, Kinzie K, Barr E, Paul S, Salbenblatt C, Soda E, Vazquez A, Peloquin CA, Levin M. Kinetics and Determining Factors of the Virologic Response to Antiretrovirals During Pregnancy. Infect Dis Obstet Gynecol. 2009;2009:621780. Epub 2010 Jan 10. PMID: 20130816 100. Façanha MC, Gondim AM, Pinheiro VG, Barroso EC, Peloquin CA, Guerrant RL, Lima AA. Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis. Braz J Infect Dis. 2009 Jun;13(3):210-7. PMID: 20191199 102. Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother. 2010 Oct;65(10):2172-5. Epub 2010 Aug 6. PMID: 20693172

103. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011 Jan;55(1):239-45. Epub 2010 Oct 11. PMID: 20937781 104. De Groote MA, Gilliland JC, Wells CL, Brooks E, Woolhiser LK, Gruppo VR, Peloquin CA, Orme IM, Lenaerts A. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against M. tuberculosis. Antimicrob Agents Chemother. 2011 Mar;55(3):1237-47. Epub 2010 Dec 6 PMID: 21135176 105. Ahmad Z, Minkowski A, Peloquin CA, Williams K, Grosset JH, Nuermberger EL. Activity of the fluoroquinolone DC-159a in the initial and continuation treatment of murine tuberculosis. Antimicrob Agents Chemother. 2011 Apr;55(4):1781-3. Epub 2011 Jan 31. PMID: 21282421 106. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH. Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune Deficient MiceAm J Respir Crit Care Med. 2011 May 1;183(9):1254-61. Epub 2011 Feb 17. PMID: 21330452


A. Original research papers published in refereed journals 107. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011; 55: 5485-92. Epub 2011 Sep 19. PMID: 21930883 108. Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JA. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. Pharmaceutical Research. 2012; 29:972-82. Epub 2011 Dec 9. PMID: 22161308 109. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis WS, Mdluli KE, Nuermberger EL. Sterilizing activity of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. Epub 2012 Apr 2. PMID: 22470112 110. Tsuji BT, Brown T, Parasrampuria R, Brazeau D, Forrest A, Kelchlin PA, Holden PN, Peloquin CA, Hanna D, Bulitta J. Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus. Antimicrob Agents Chemother. 2012 Jul;56(7):3712-9. Epub 2012 Apr 23. PMID: 22526313 111. Dutta NK, Illei PB, Peloquin CA, Pinn ML, Nuermberger EL and Karakousis PC. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2012 Jul;56(7):3726-31. Epub 2012 Apr 30. PMID: 22547623 112. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4. PMID: 22664964 113. Tsuji BT, Brown T, Bulitta J, Forrest A, Brazeau D, Kelchlin PA, Holden PN, Peloquin CA, Skerlos L,Hanna D. Pharmacodynamics of Early, High Dose Linezolid against Vancomycin-Resistant Enterococci (VRE) with Elevated MICs and Pre-Existing Genetic Mutations. J Antimicrob Chemother. 2012 Sep;67(9):2182-90. doi: 10.1093/jac/dks201. Epub 2012 Jun 8. PMID: 22685161 114. van Ingen J, Egelund EF**, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL.. The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium Avium Complex Disease Treatment. Am J Respir Crit Care Med. 2012 Sep 15;186(6):559-65. doi: 10.1164/rccm.201204-0682OC. Epub 2012 Jun 28. PMID: 22744719 115. Matthias KR, Nix DE, Peloquin CA, Graham ML. Poor Absorption of High-Dose Posaconazole in Pediatric Bone Marrow Transplant Patients. Ann Pharmacother. 2012 Sep;46(9):e22. doi: 10.1345/aph.1Q456. Epub 2012 Aug 7. PMID: 22872751


A. Original research papers published in refereed journals 116. Glover TL, Goodin BR, Horgas AL, Kindler LL, King CB, Sibille K, Peloquin CA Riley III, JR, Staud R, Bradley LA, Fillingim RB. Vitamin D, Race, and Pain. Arthritis Rheum. 2012 Dec;64(12):3926-35. doi: 10.1002/art.37687. PMID: 23135697 117. Dutta NK, Alsultan A, Peloquin CA, Karakousis PC. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. Antimicrob Agents Chemother. 2013 Mar;57(3):1535-7. doi: 10.1128/AAC.01933-12. Epub 2013 Jan 7. PMID: 23295923 118. Egelund EF**, Egelund TA, Ng JS, Wassil SK, Peloquin CA. Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis. Pharmacotherapy. 2013 Jan;33(1):e1-8. doi: 10.1002/phar.1172. PMID: 23307552 119. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. Contribution of Moxifloxacin or Levofloxacin in Second-line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis. Am J Respir Crit Care Med. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC. PMID: 23593945 120. Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13. Epub 2013 Jun 3. PMID: 23733473 121. Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, Moore JL, Houpt ER, Kibiki GS, Heysell SK Plasma drug activity in multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2014 Feb;58(2):782-8. doi: 10.1128/AAC.01549-13. Epub 2013 Nov 18. PMID: 24247125 122. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, Mac Kenzie W, Peloquin CA. The Pharmacokinetic Interaction Between Raltegravir and Rifapentine in Healthy Volunteers. J Antimicrob Chemother. 2014 Apr;69(4):1079-85. doi: 10.1093/jac/dkt483. Epub 2013 Dec 15. PMID: 24343893 123. Weiner M, Savic RM, Mac Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Borisov A, Prihoda TJ, Gelfond J, Wing R, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly with Rifapentine and Isoniazid for Latent Tuberculosis Infection. Journal of the Pediatric Infectious Diseases Society pp. 1-14, 2014. DOI:10.1093/jpids/pit077 124. Kwara A, Cao L, Poethke P, Kurpewski KT, Mahjoub B, Court MH, Peloquin CA. Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Drug Interactions with Efavirenz. Pharmacotherapy. 2014 Mar;34(3):265-71. doi: 10.1002/phar.1388. Epub 2014 Jan 13. PMID: 24420746


A. Original research papers published in refereed journals 125. Brock AP, Isaza R, Egelund EF, Hunter RP, and Peloquin CA. The Pharmacokinetics of a Single Oral or Rectal Dose of Concurrently Administered Isoniazid, Rifampin, Pyrazinamide, and Ethambutol in Asian Elephants (Elephas maximus). J Vet Pharmacol Ther. 2014 Mar 29. doi: 10.1111/jvp.12119. [Epub ahead of print] PMID: 24684601 126. Egelund EF, Weiner W, Singh Rp, Prihoda TJ, Derendorf H, Mac Kenzie WR, and Peloquin CA. Protein Binding of Rifapentine and the 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2014 May 19. pii: AAC.01730-13. [Epub ahead of print] PMID: 24841270


B. Review papers published in refereed journals (29 papers: 12 first author, 8 senior author, 9 other) 1. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, and Schentag JJ. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrobial Agents and Chemotherapy 1991; 35: 1947-1952. 2. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, and Schentag JJ. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrobial Agents and Chemotherapy 1991; 35: 1953-1959. 3. Peloquin CA. Therapeutic Drug Monitoring: Principles and Application in Mycobacterial Infections. Drug Therapy 1992; 22:31-6. Co-circulated in P&T 1992; 17: 1465-1475. 4. Peloquin CA. Controversies in the management of Mycobacterium avium complex (MAC) infection. Annals of Pharmacotherapy 1993; 27: 928-937. 5. Peloquin CA. Pharmacology of the Antimycobacterial Drugs. Medical Clinics of North America 1993, 77: 1253-1262. 6. Peloquin CA. Mycobacterial Infections. Pharmacotherapy 1993, 13: 634-639. 7. Peloquin CA, Berning SE. Infections due to Mycobacterium tuberculosis. Annals of Pharmacotherapy 1994; 28: 72-84. 8. Briceland LL, Cleary JD, Fletcher CV, Healy DP, Peloquin CA. Anti-infectives Update. Annals of Pharmacotherapy 1995; 29: 1035-1040. 9. Peloquin CA, Berning SE. Tuberculosis and multi-drug resistant tuberculosis in children. Pediatric Nursing 1995, 21: 566-572. 10. Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clinics in Laboratory Medicine 1996; 16: 717-729. 11. Peloquin CA. Mycobacterium avium Complex Infection: Pharmacokinetic and Pharmacodynamic Considerations That May Improve Clinical Outcomes. Clinical Pharmacokinetics 1997; 32: 132-144. 12. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clinics in Chest Medicine 1997; 18: 79-87. 13. Amsden GW, Peloquin CA, Berning SE. The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Drugs 1997, 54: 69-80.


B. Review papers published in refereed journals 14. Peloquin CA. Contemporary management of tuberculosis. Journal of Infectious Disease Pharmacotherapy 1998; 3: 41-52. 15. Burman WJ, Gallicano K, Peloquin CA. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis. Clinical Infectious Diseases 1999; 28: 419-430. 16. Burman WJ, Gallicano K, Peloquin CA. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibiotics. Clinical Pharmacokinetics 2001: 40: 327-341. 17. Peloquin CA. Pharmacological Issues in the Treatment of Tuberculosis. Ann NY Acad Sci 2001; 953: 157-164. 18. Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs 2002; 62: 2169-2183. 19. ATS / CDC / IDSA: Treatment of Tuberculosis. Contributor: Peloquin CA. Am J Respir Crit Care Med. 2003; 167: 603-662. 20. Vaidyanathan S, Peloquin CA, Wyndaele JJ, Buczynski AZ, Almog Y, Hughes P, Soni BM, Singh G. Amikacin dosing and monitoring in spinal cord injury patients: Variation in clinical practice between spinal injury units and differences in experts' recommendations. TheScientificWorldJournal 2006; 6: 187-199. 21. Saukkonen JJ, Bernardo J, Cohn D, Gordin F, Jasmer R, Jereb J, Nolan C, Nunes D, Peloquin C, Shenker S, Sterling T, Strader D, Venkataramanan, R. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. 22. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009; 10: 381-401. PMID: 19191677 23. Sabarinath SN, Wu B, Peloquin CA, Derendorf H. Pharmacometrics in dose finding of anti-retroviral and anti-tubercular drugs. Infect Disord Drug Targets. 2011 Apr 1;11(2):157-66. PMID: 21406049 24. Egelund EF, Barth AB, Peloquin CA. Population Pharmacokinetics and its role in Anti-tuberculosis Drug Development & Optimization of Treatment Curr Pharm Des. 2011 Aug 12. [Epub ahead of print] PMID: 21834766 25. Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald PR, Schaaf HS. Paediatric use of second-line tuberculosis agents: a review. Tuberculosis (Edinb). 2011 Nov 24. [Epub ahead of print] PMID: 22118883 26. Lauzardo M, Peloquin CA. Anti-tuberculosis Therapy for 2012 and Beyond. Expert Opin Pharmacother. 2012; 13: 511-26.


B. Review papers published in refereed journals 27. Srivastava S, Peloquin CA, Sotgiu G and Migliori GB. Therapeutic Drug Management: is it the future of MDR-TB treatment? Letter. Eur Respir J. 2013 Dec;42(6):1449-53. doi: 10.1183/09031936.00073213. PMID: 24293417 28. Obeng AO, Egelund EF, A, Peloquin CA, Johnson JA. CYP2C19 Polymorphisms and Voriconazole Therapy: Are We Ready for Clinical Implementation of Pharmacogenomics? Pharmacotherapy. 2014 Feb 7. doi: 10.1002/phar.1400. [Epub ahead of print] PMID: 24510446 29. Alsultan A, Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis, an update. Drugs. 2014 May 21. [Epub ahead of print] PMID: 24846578 C. Book Chapters (37 chapters: 18 first author, 18 senior author, 1 other) 1. Peloquin CA, Antituberculosis Drugs: Pharmacokinetics. In Heifets, L, ed. Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. CRC Press, Boca Raton, 1991, p 59-88. 2. Peloquin CA. Antimicrobial Therapy. In Bittar EE and Bittar N, Eds. Principles of Medical Biology. Volume 9A: Microbiology. Jai Press, Greenwich, CT, 1997, p 175-198. 3. Berning SE, Peloquin CA. Antimycobacterial Agents: Ethionamide. In Yu VL, Merigan TC, Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams and Wilkins, Baltimore, MD, 1998, p 650-654. 4. Berning SE, Peloquin CA. Antimycobacterial Agents: Para-aminosalicylic acid. In Yu VL, Merigan TC, Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams and Wilkins, Baltimore, MD, 1998, p 663-668. 5. Berning SE, Peloquin CA. Antimycobacterial Agents: Cycloserine. In Yu VL, Merigan TC, Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams and Wilkins, Baltimore, MD, 1998, p 638-642. 6. Berning SE, Peloquin CA. Antimycobacterial Agents: Isoniazid. In Yu VL, Merigan TC, Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams and Wilkins, Baltimore, MD, 1998, p 654-663. 7. Morris AB, Kanyok TP, Scott J, Peloquin CA, Berning SE. Rifamycins. In Yu VL, Merigan TC, Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams and Wilkins, Baltimore, MD, 1998, p 901-963. 8. Peloquin CA, Iseman MD. Antimycobacterial Agents. In Root RK, Ed. Clinical Infectious Diseases: A Practical Approach. Oxford University Press, New York, NY 1999, p 327-335.


9. Peloquin CA, Ebert SC. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 4th ed. Appleton & Lange, Stamford, CT, 1999, p 1717-1736.


C. Book Chapters 10. Peloquin CA, Auclair B. Pharmacology of the second-line antituberculosis drugs. In Portaels F, Bastian I, Eds. MDR Mycobacterium tuberculosis. Kluwer Academic Publications, Dordrecht, The Netherlands, 2000, p 163-174. 11. Peloquin CA. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA, Eds. Drug Interactions in Infectious Diseases. Humana Press, Totowa, NJ, 2000, p 109-120. 12. Peloquin CA. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 5th ed., McGraw Hill, New York, 2002, p 1917-1937. 13. Peloquin CA. Clinical pharmacology of the anti-tuberculosis drugs. Davies PDO, Ed. Clinical Tuberculosis, 3rd Ed. Arnold Publishers, London, England, 2003, p 171-190. 14. Namdar R, Peloquin CA. Ethionamide. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial Agents. Esun Technologies, LLC, 2005, p 533-538. 15. Peloquin CA. Para-aminosalicylic acid. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial Agents. Esun Technologies, LLC, 2005, p 551-558. 16. Peloquin CA. Cycloserine. I In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial Agents. Esun Technologies, LLC, 2005, p 517-522. 17. Burman WJ, Peloquin CA. Isoniazid. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial Agents. Esun Technologies, LLC, 2005, p 539-550. 18. Namdar R, Morris AB, Peloquin CA. Rifamycins for Nonmycobacterial Infections. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial Agents. Esun Technologies, LLC, 2005, p 403-454. 19. Peloquin CA, Vernon A. Antimycobacterial Agents: Rifamycins for Mycobacterial Infections. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial Chemotherapy and Vaccines, 2nd edition, Volume II: Antimicrobial Agents. Esun Technologies, LLC, 2005, p 383-402. 20. Peloquin CA. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 6th ed. McGraw Hill, New York, 2005 p 2015-2034.


21. Namdar R, Ebert S, Peloquin CA. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA, Eds. Drug Interactions in Infectious Diseases, 2nd Edition. Humana Press, Totowa, NJ, 2006, p 191-214. 22. Nuermberger EL, Grosset JH, Peloquin CA. Pharmacological Issues in the Development of New Antituberculosis Drugs. Development of New Antituberculosis Drugs. Yew WW, Ed. Nova Science Publishers, Hauppauge NY, 2006, p 53-73. 23. Peloquin CA, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice. McGraw Hill, New York, 2008. p 1105-1116. 24. Peloquin CA. Clinical pharmacology of the anti-tuberculosis drugs. Davies PDO, Barnes PF, Gordon SB, Ed. Clinical Tuberculosis, 4th Ed., Hodder Arnold, London, 2008 25. Peloquin CA. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 7th ed. McGraw Hill, New York, 2008 p 1839-1856. 26. Namdar R, Peloquin CA. Tuberculosis. In Pharmacotherapy in Primary Care, Linn WD, Wofford MR, O;Keefe ME, Posey LM, Eds. McGraw Hill, New York, 2008 p 463-473. 27. Namdar R, Morris AB, Peloquin CA. Rifamycins for Nonmycobacterial Infections. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors. Antimicrobial Chemotherapy and Vaccines Vol II: Antimicrobial Agents 2008. Pittsburgh; Esun Technologies, LLC. Available from: http://www.antimicrobe.org/index.asp

28. Namdar R, Peloquin CA. Ethionamide. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors. Antimicrobial Chemotherapy and Vaccines Vol II: Antimicrobial Agents 2010. Pittsburgh; Esun Technologies, LLC. Available from: http://www.antimicrobe.org/index.asp 29. Peloquin CA, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice, 2nd Ed. McGraw Hill, New York, 2010. p 1253-1263. 30. Peloquin CA, Namdar R. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 8th ed. McGraw Hill, New York, 2011 p 1931-1949. 31. Egelund EF, Peloquin CA. Current Issues in Tuberculosis Pharmacokinetics. In Donald PR, van Helden PD, Eds. Antituberculosis Chemotherapy. Prog Respir Res. Basel, Karger, 2011, vol 40, pp 153–160.


C. Book Chapters 32. Namdar R, Peloquin CA. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA, Pai MP Eds. Drug Interactions in Infectious Diseases, 3rd Edition. Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY, 2011, p 401-424. 33. Barth AB, Egelund EF, Peloquin CA. Rifamycin Use in HIV-infected Patients with Tuberculosis. Yi-Wei Tang, Ed. Recent Translational Research in HIV/AIDS. InTech, Rijeka, Croatia. 2011. ISBN 978-953-307-719-2 34. Namdar R, Peloquin CA. Tuberculosis. In PSAP VII Infectious Diseases, ACCP, Lenexa, KS 2012, p. 53-74. 35. Peloquin CA, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice, 3rd Ed. McGraw Hill, New York, 2013, p 1315 – 1327. 36. Namdar R, Lauzardo M, Peloquin CA. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 9th ed. McGraw Hill, New York, 2014, p 1787-1806. 37. Abdullah Alsultan, Peloquin CA. Clinical pharmacology of the anti-tuberculosis drugs. Davies PDO, Gordon SB, Davies G, Ed. Clinical Tuberculosis, 5th Ed. CRC Press, Boca Raton, 2014, p 209 – 228.


D. Other Publications (33 papers: 25 first author, 6 senior author, 2 other) 1. Peloquin CA. Stereospecific approaches in the synthesis of phenethanolamine analogues. Honors Thesis. University of Connecticut School of Pharmacy. December, 1981 2. Peloquin CA. Trimethoprim-Sulfamethoxazole. Drug Information Bulletin, Duke University Medical Center. March, 1983. 3. Peloquin CA. Trimethoprim-Sulfamethoxazole. Patient Information Article. North Carolina Medical Journal. 1983; 44: 438. 4. Peloquin CA. Beta-Lactam antibiotics and bleeding disorders. Drug Information Bulletin, Duke University Medical Center. February, 1984. 5. Nix, DE, Peloquin CA. Storing extra calibration curves in the TDx assay system. Clinical Pharmacy 1988; 7: 792. 6. Peloquin CA. Fighting Tuberculosis with Old Weapons. DICP, The Annals of Pharmacotherapy 1990; 24: 883-884. 7. Peloquin CA. The Dosing of Antimycobacterial Agents (Letter). Clinical Pharmacy 1991; 10: 664-665. 8. Peloquin CA. Shortages of Antimycobacterial Drugs (Letter). New England Journal of Medicine 1992; 326: 714. 9. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of Anti-tuberculosis medications by a patient with AIDS (Letter). New England Journal of Medicine 1992; 327: 1817-1818. 10. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. New England Journal of Medicine 1993; 329: 1122-1123. 11. Peloquin CA, Berning SE. Comment: Intravenous Streptomycin (letter). Annals of Pharmacotherapy 1993, 27: 1546-1547. 12. Peloquin CA. Book Review. Tuberculosis: Pathogenesis, Protection, and Control. Annals of Pharmacotherapy 1995, 29: 1054. 13. Berning SE, Peloquin CA. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. (letter) Clinical Infectious Diseases 1996; 22: 885. 14. Peloquin CA. Treatment and Prophylaxis of Disseminated Mycobacterium avium Complex Infections in Patients with AIDS (DMAC). (editorial) Drug Benefit Trends 1996; 8: 16-17.


D. Other Publications 15. Peloquin CA. Quinolones and Tuberculosis (editorial). Annals of Pharmacotherapy 1996; 30: 1034-1035. 16. Peloquin CA, Berning SE. Advice on the treatment of drug-resistant tuberculosis. (letter) Am J Health-Syst Pharm. 1997; 54: 700-701. 17. Peloquin CA, Berning SE. Advice on the treatment of Mycobacterium avium complex infection. (letter) Am J Health-Syst Pharm 1997; 54: 1208-1209

18. Peloquin CA, Berning SE, Huitt GA, Iseman MD. Levofloxacin for drug-resistant Mycobacterium tuberculosis. (letter) Annals of Pharmacotherapy 1998; 32: 268-269. 19. Peloquin CA. Serum Concentrations of the Antimycobacterial Drugs (editorial) Chest 1998; 113: 1154-1155.

20. Peloquin CA. Rifampin Stability (letter). Therapeutic Drug Monitoring 1998; 20: 450-451. 21. Peloquin CA. Therapeutic Drug Monitoring in Antituberculosis Chemotherapy (letter). Therapeutic Drug Monitoring 1999; 21: 426-427. 22. Peloquin CA, Berning SE, Huitt GA, Iseman MD. (letter) AIDS and TB drug absorption. International Journal of Tuberculosis and Lung Disease 1999; 3: 1143-1144. 23. Peloquin CA. Tuberculosis Drug Serum Levels (letter). Clinical Infectious Diseases 2001; 33: 584-585. 24. Peloquin C. What is the right dose of rifampin? Int J Tuberc Lung Dis 2003; 7: 3-5. 25. Goldberg S, Hanson D, Peloquin CA. Rifamycin treatment for tuberculosis in a patient on atenolol: less interaction with rifabutin than with rifampin. (letter) Clinical Infectious Diseases 2003; 37: 607-608. 26. Peloquin C. Use of Therapeutic Drug Monitoring in Tuberculosis Patients (editorial) Chest 2004; 126: 1722-1724. 27. Peloquin CA, Durbin D, Childs J, Sterling TR, Weiner M. Stability of Anti-Tuberculosis Drugs Mixed in Food. Clinical Infectious Diseases 2007; 45: 521. 28. Peloquin C. Aminoglycoside nephrotoxicity. (letter) Antimicrob Agents Chemother. 2010; 54: 2750-2751. PMID: 20480959 29. Stein GE, Smith CL, Peloquin CA, Mosher B, Dybas L, Kepros JP. Bile and Gallbladder Tissue Concentrations of Moxifloxacin in Patients with Acute Cholecystitis. Ann Pharmacother. 2010 Jun 15. [Epub ahead of print] PMID: 20551298


D. Other Publications 30. Peloquin CA Pharmacokinetic Mismatch of Tuberculosis Drugs. Antimicrob. Agents Chemother. 2012, 56:1666. 31. Egelund EF**, Peloquin CA. Pharmacokinetic variability and TB treatment outcomes, including acquired drug resistance. Invited Editorial. Clin Infect Dis. 2012 Jul;55(2):178-9. doi: 10.1093/cid/cis366. Epub 2012 Mar 30. PMID: 22467672 32. Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH. Reply to "contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. PMID: 23341430 33. Egelund EF, Mohamed M, Fennelly KP, Peloquin CA. Concomitant Use of Carbamazepine and Rifampin in a Patient with Mycobacterium Avium Complex and Seizure Disorder. Journal of Pharmacy Technology 2014; 30: 93-96. E. Books and Guides 1. Contributor to: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2007. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm 2. Contributors: Braun JT, Daley CL, Desmond EP, Flood JM, Kawamura LM, Loeffler AM, Mase SR, Pai M, Peloquin C, Raftery A, Salfinger M, Schecter G, Seaworth BJ, Smith KL, Wallis K. Editors: Loeffler AL, Daley CL, Flood JM, Schecter G. Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2008: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 2nd edition. 3. Contributors: Loeffler AL, Peloquin CA, Schecter G. Editors: Loeffler AL, Schecter G, Daley CL, Flood JM. Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2009: Tuberculosis Drug Information Guide. 4. Contributor to: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Vol. 58 / RR-4, April 10, 2009. 5. Contributors: Loeffler AL, Peloquin CA, Schecter G. Editors: Loeffler AL, Schecter G, Daley CL, Flood JM. Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2012: Tuberculosis Drug Information Guide, 2nd edition. 6. Contributor to: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Downloaded from http://aidsinfo.nih.gov/guidelines on 5/14/2013 7. Contributor to: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 2013. Available at URL:http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/pdf/tbhiv.pdf


F. Manuscripts Accepted for Publication G. Chapters Accepted for Publication Peloquin CA. Pharmacometrics and Tuberculosis. In Derendorf H and Schmidt S, Eds. Applied Pharmacometrics. Egelund EF, Peloquin CA. Antimycobacterial Drugs. In Lippincott’s Illustrated Reviews: Pharmacology, 6th Edition. H. Manuscripts Submitted for Publication Peloquin CA. Pharmacometrics in Tuberculosis. In Derendorf H and Schmidt S, Eds. Henry Stewart Talks. Villanueva L, McCabe T, Egelund, EF, Zou B, Vijayan, V, Peloquin, CA. Voriconazole Monitoring in Children with Invasive Fungal Infections Kwara A, Lartey M, Kenu E, Obo-Akwa A, Zigah F, Mahjoub B, Peloquin CA. Pharmacokinetics of isoniazid, rifampin and pyrazinamide in Ghanaian Patients with Tuberculosis and Human Immunodeficiency Virus Coinfection

Revised 5-14

Documents

CHARLES ARTHUR PELOQUIN, PHARM.D. CURRICULUM VITAE, … · Internal Medicine 1989; 149: 2269-2273. 3. ... meningitis: Clinical problems and concentrations of second-line anti-tuberculous